INTRODUCTION
Mitochondria are ubiquitous intracellular organelles in which oxidative metabolism occurs to generate the majority of cellular energy in the chemical form of ATP [1] . Approximately 1500 proteins exist within mitochondria, with origins from two distinct cellular genomes. The vast majority of mitochondrial proteins are encoded by the nuclear genome (nDNA), whereas only 13 mitochondrial proteins that are all core structural subunits of complexes I, III, IV, and V in the oxidative phosphorylation (OXPHOS) pathway are encoded in the mitochondrial genome (mtDNA) [2] . Primary mitochondrial disease (PMD) is a highly heterogeneous collection of inherited genetic-based disorders that share in common disrupted energy metabolism due to impaired oxidative phosphorylation (OXPHOS) capacity. The broad and highly variable but commonly progressive phenotypic spectrum ranges from adult-onset, isolated organ system involvement to infantile-onset, multisystemic, lethal disease [2] . Multi-systemic involvement that may affect nearly every organ has been described, leading to immense variation of clinical phenotype that can pose a diagnostic challenge [3] . In a recent survey of self-reported PMD individuals (n ¼ 270), both pediatric and adult PMD patients reported a mean of 16 clinical symptoms, highlighting the substantial burden of this disease [4 & ]. Although PMDs are individually rare, they have a collective minimal prevalence of 1 in 4300 [5] . To date, pathogenic variants in more than 350 genes have been associated with PMD [6 && ,7] . Since the early characterization of cellular energy production within mitochondria in the 1950s and the discovery of causal mtDNA variants only three decades ago [8] [9] [10] , knowledge of the diverse molecular causes of PMD and deleterious effects of pathogenic variants has dramatically increased. This, in turn, has led to the elucidation of the underlying gene defects in individual patients, with increasing potential to develop specific therapeutic strategies [2] . Further, recent approval in the United Kingdom of novel reproductive technologies such as mitochondrial replacement technologies (MRTs) holds potential to prevent the transmission of maternally-inherited mtDNA disorders in families with known pathogenic variants [11] . Here, we summarize recent advances in PMD molecular causes, diagnostic approach, and emerging treatment approaches.
MOLECULAR CAUSES OF PRIMARY MITOCHONDRIAL DISEASE
Since the pioneering discoveries of pathogenic variants in mtDNA in 1988 [8, 9] and pathogenic variants in nuclear genes encoding proteins necessary for mitochondrial function in 2000-2001 [12] [13] [14] , pathogenic variants in more than 350 genes across both genomes have been recognized to cause PMD [6 && ,7,10] .
Mitochondrial DNA
The mitochondrial genome is comprised of 16,569 base pairs that encode 37 genes, including 13 proteins, 22 transfer RNAs (tRNA), and 2 ribosomal RNAs (rRNA). mtDNA is exclusively maternallyinherited through the oocyte, and replicates independently of the cell cycle. There are multiple copies of mtDNA in each mitochondrion, and multiple mitochondria per cell. mtDNA variants may exist in a state of homoplasmy, meaning in all mitochondrial genomes within a mitochondrion or cell, or in a state of heteroplasmy, meaning the variant is only present in a portion of the mitochondrial genomes. The proportion of mitochondrial genomes with a specific variant may differ greatly between a given individual's tissues and among members of the same family. In general, the proportion of mitochondrial genomes that harbor a pathogenic variant directly correlates with disease severity [1] . Many healthy individuals have low levels of pathogenic mtDNA variants accumulate in some tissues with age, although if a pathogenic variant reaches a certain threshold heteroplasmy level, which may vary greatly by tissue energy demand, phenotypic symptoms may develop over time.
While the basic concepts of heteroplasmy and threshold effect hold true for many pathogenic mtDNA variants, the correlation of precise heteroplasmy levels among various tissues with disease onset and tissue-specific manifestations remains poorly understood. Grady et al. [15] recently characterized heteroplasmy levels in several tissues (blood, n ¼ 231; urine, n ¼ 235; skeletal muscle, n ¼ 77) over time in a cohort of individuals with the well characterized pathogenic mtDNA variant m.3243A>G that may cause a range of clinical syndromes from mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) to Leigh syndrome or maternally inherited diabetes and deafness (MIDD). Many of the m.3243A>G carriers were clinically affected, with assessment made to correlate heteroplasmy level, disease burden, and disease progression [15] . Results showed greatest correlation between heteroplasmy levels in blood and urine > muscle and blood > muscle and urine. Muscle heteroplasmy levels did not correlate with age, whereas both blood and urine heteroplasmy levels declined with age. Overall, blood heteroplasmy levels decreased at a rate of
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Precision therapies are emerging based on improved understanding of mitochondrial disease cause and pathophysiology in PMD individuals. approximately 2.3% per year when adjusted for age. Men had 19.2% higher urine heteroplasmy levels than women. Urine heteroplasmy levels showed the greatest variability, up to 55%, compared to 15% in blood. Age-adjusted blood heteroplasmy levels showed greatest correlation with disease burden and progression. Higher muscle mtDNA copy number was associated with a decreased disease burden, providing valuable information about the role of mitochondrial biogenesis in m.3243A>G clinical phenotype penetrance. While this study informs the correlation of muscle, blood, and urine heteroplasmy levels of the common m.3243A>G pathogenic variant with disease progression and burden, understanding the cause of the discrepancies in heteroplasmy levels between tissues remains speculative. Prior studies have suggested that pathogenic mtDNA variants are selected against in rapidly dividing tissues such as hematopoietic stem cells that is reflected in blood heteroplasmy levels [16] . This phenomenon would not be seen in muscle, and urine samples include many epithelial cell types at varying concentrations that may potentially contribute to observed variations in heteroplasmy levels [15] .
Given that individuals who carry low heteroplasmy levels of pathogenic mtDNA variants may be asymptomatic, heteroplasmy shift therapy is a potential therapeutic strategy for PMD, with the goal to decrease the heteroplasmy level of a given pathogenic mtDNA variant in affected individuals. Different approaches have been considered in the research setting, including use of mitochondrialtargeted transcription activator-like effector nucleases (mitoTALENS), which utilize engineered nucleases to selectively degrade specific target mtDNA genomes [17, 18] . Yang et al. [19] showed that m.3243A>G pathogenic variant heteroplasmy levels in induced pluripotent stem cells (iPSCs) could be eliminated by mitoTALENs, with 'rescued' cells having normal energy production. When tested in porcine oocytes, mutant heteroplasmy levels were similarly decreased. Yahata et al. [20] similarly showed that mitoTALENs could be used to decrease mutation heteroplasmy levels in iPSCs generated from individuals with the known pathogenic complex I ND5 subunit m.13513G>A variant.
As mtDNA is maternally inherited through the oocyte, affected individuals with mtDNA-related disease may either inherit the variant from their mother or it may occur de novo in the oocyte or embryo that forms the affected individual. Whether the mother of an affected individual is symptomatic depends on whether she carries the same mutation in her somatic cells, and if so, at what level of heteroplasmy [21] . Until recently, the only reliable reproductive options for women with mtDNA pathogenic variants to assure their offspring did not inherit the disease-causing variant were either adoption or utilizing an egg donor, with prenatal heteroplasmy testing largely considered unreliable.
Traditional prenatal testing options such as chorionic villus sampling (CVS) at 10-12 weeks' gestation and amniocentesis at 16-20 weeks' gestation may be available to women with heteroplasmic mtDNA pathogenic variants, although limitations exist. The biological variability of mtDNA mutation heteroplasmy load in tissues tested and a lack of clear correlation between mutant load assessed (whether in placental chorionic villus cells or fetal amniotic fluid cells) and clinical outcome in the resulting child complicate interpretation of any results. This is exemplified by a recent study by Vachin et al. [22] , which sought to evaluate how informative placental heteroplasmy level testing was when compared to testing heteroplasmy levels in chorionic villi, amniotic fluid, cord blood, and fetal tissues. Enrolling individuals who carried several different pathogenic mtDNA variants, heteroplasmy levels were similar among all tissue samples tested when pathogenic variants were present at the extremes, either above 80% or below 20%. When heteroplasmy levels fell in an intermediate range, much greater variability between tissue heteroplasmy levels was seen. Significantly more variance was also seen in tissues obtained from full-term fetuses as compared to tissues obtained from pregnancies terminated between 12 and 18 weeks' gestation. This study highlights the difficulty both in interpreting heteroplasmy levels obtained prenatally and in accurately predicting health outcomes for the resulting child.
Preimplantation genetic diagnosis, or PGD, of embryos in the setting of in-vitro fertilization (IVF) for mtDNA mutations has been a challenge due to both biological and technologic considerations [23] . Prior studies have suggested a low likelihood of clinical disease occurring in the resulting child when an embryo is found to have a mutation heteroplasmy load below 18% [24] . However, there is no way to absolutely guarantee an embryo will be generated with heteroplasmy levels below this threshold, that the mutation load in the embryo will not stochastically increase in any tissues of the resulting child sufficient to cause even mild clinical disease throughout their lifetime, nor that this threshold is reliable for all pathogenic mtDNA variants. While these limitations still exist, this option has been further technically refined in the past year, as Sallevelt et al., 2017 showed that assessing mtDNA heteroplasmy level in a single blastomere from an embryo carries a low diagnostic error rate and has improved outcomes on live birth delivery as compared to assessing two blastomeres [25] . As such, PGD may be a viable option for pathogenic mtDNA variant detection and selection of embryos with low heteroplasmy levels in certain instances, but is not universally efficacious [23] .
In contrast to traditional prenatal testing and PGD, MRT by pronuclear transfer (PNT) involves transplantation of the nuclear genome from the zygote of an affected woman to an enucleated zygote from an unaffected donor [11, 26] , theoretically allowing a woman carrying a pathogenic mtDNA mutation to have an unaffected, genetically related child. Another MRT technique that has been developed in the research setting is maternal spindle transfer (MST), which is similar to pronuclear transfer but involves manipulation of oocytes rather than zygotes. Without MRT, reliable reproductive options for women with mtDNA pathogenic variants are limited [27] . Proof-of-concept studies indicated that MRT is compatible with the development of human embryos to the blastocyst stage [28] . Further, the technical feasibility of MRT has been demonstrated in animal models, and several generations of resulting non-human primate offspring generated by the MST method have now been born without obvious disease [29] .
Given the relatively low levels (below 1-2%) of mtDNA carryover during PNT [30] and MST [31] in human embryos, and polar body transfer in mice [32] , these techniques are likely to be highly effective in not just identifying but actively reducing the risk of severe mtDNA disease in children of women known to carry pathogenic mtDNA variants that cause severe, life-threatening mitochondrial diseases. Generating new combinations of mitochondrial and maternal nuclear genome backgrounds has been proposed to possibly lead to more subtle adverse outcomes such as impaired cognitive function [33] , but this theoretical risk has not been proven nor studied in humans [34] . Clearly, longterm monitoring would be needed throughout childhood, and probably well into adulthood, of any child born following use of MRT techniques to determine their mtDNA mutation load in different tissues over time and to identify any negative health outcomes that may change the risk-benefit balance [27, 35] .
MRT has now been approved in the United Kingdom to be performed in selected sites on a clinical basis for women known to carry an mtDNA pathogenic mutation that causes severe disease on a caseby-case basis [26] . The ethical issues around MRT remain considerable, including concerns on legal parenthood rights, insufficient knowledge regarding the safety of MRT that will remain until several generations of people have been born from the procedure, and the possibility of conflicting ancestry and self-identity in the resulting child [34] . The legality and regulation of the technique varies markedly between countries, with approval only currently possible under certain conditions as specified above in the United Kingdom, where there is a highly regulated environment for IVF techniques [11] . Government and legal hurdles remain in place in many countries including the United States that prohibit research study or clinical utilization of MRT [27] .
Nuclear DNA
Primary mitochondrial disease is commonly caused by pathogenic variants in nuclear genes, which can occur in any Mendelian pattern including autosomal dominant, autosomal recessive, or X-linked inheritance. Reproductive options for individuals with pathogenic variant(s) in a nuclear gene exist to the same extent as for other Mendelian conditions. Nuclear DNA pathogenic variants causing PMD are most commonly inherited in an autosomal recessive manner, particularly for childhood-onset diseases. mtDNA pathogenic variants are more commonly causative of adult-onset primary mitochondrial disease. However, improved diagnostic testing has demonstrated that mutations in both genomes can variably cause pediatric and adult-onset disease.
Nuclear DNA genes in which mutations cause PMD encode proteins that have an array of roles within mitochondria, including as assembly factors or structural subunits of the electron transport chain (ETC) complexes; mtDNA maintenance; mtDNA replication, transcription, or translation; mitochondrial import and export; mitochondrial dynamics; and others.
NOVEL GENES AND EXPANDING PHENOTYPES
The advent of molecular technologies has accelerated the identification of PMD genes. Over the past 12 months alone, more than a dozen novel PMD genes and/or pathogenic variant(s) have been discovered (Table 1 ). In addition, the delineation of previously well-recognized clinical syndromes has expanded in light of improved genomic diagnosis ( Table 2) . Several excellent PMD review articles have been written in the past year (Table 3) .
DIAGNOSIS OF PRIMARY MITOCHONDRIAL DISEASE
While summarizing the diagnostic approach to PMD is outside the scope of this review, tremendous 
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Summary of all 92 affected individuals reported to date [82] improvements in the diagnostic approach have been achieved in the molecular era of PMD [21, 90] . Due to the challenges presented by significant clinical heterogeneity and lack of reliable biomarkers to detect or exclude all possible PMD, the genomic approach now tends to be the first-line investigation coupled to a specialist clinical assessment and biochemical screen. The genomic approach has several additional advantages, allowing the genetic diagnosis of other rare treatable diseases, more than one genetic disorder in a given patient, mitochondrial disease phenocopies, and, importantly, ensuring that mitochondrial disorders are diagnosed when they may have been overlooked clinically [87] . Rapidly reducing costs have facilitated more widespread implementation of whole exome sequencing (WES) and whole genome sequencing (WGS) in large cohorts of PMD patients. The increasing application of next generation sequencing (NGS) in extended gene panels, WES, and WGS of both nuclear and mtDNA genomes to routine mitochondrial disease diagnostics has led to a dramatic increase in the PMD diagnostic yield [6 && ]. The diagnostic yield for WES in PMD in unsolved patients in whom there was a clinical suspicion of a mitochondrial disorder in Estonia was recently shown to be 50% [91] , although genetic diagnostic testing yield up to 70-90% has been reported in some centers depending on the clinical and biochemical phenotype [92] . More invasive diagnostic tests such as muscle biopsy are increasingly reserved for cases that cannot be solved by a first-line genomic diagnostic approach in a more readily accessible tissue; muscle biopsy may still be useful after genetic diagnosis has been established in some individuals to gain more understanding of their degree of mitochondrial impairment. We estimate that a muscle biopsy is required in approximately 30-40% of undiagnosed cases with suspected mitochondrial disease (author observation), more commonly in adults, in those with uninformative mtDNA sequencing in more readily accessed tissues, and in those with nonclassical symptom constellations. Despite these substantial technologic advances, the diagnostic odyssey for some patients with [83] mtDNA replication defects Overview of mtDNA maintenance and disorders arising from impaired mtDNA maintenance [84] mtDNA transcription and translation defects Overview of genes important for mtDNA transcription and translation with pathogenic variants reported, organized by place in transcription or translation process in which gene product is involved, provides overview figure and summary tables organized by genetic mutations [85] mtDNA bottleneck Summary of the mitochondrial genome bottleneck hypothesis [1] Biomarkers Biomarkers for primary mitochondrial disease
Overview of currently utilized biomarkers and summary of novel approaches [86] Natural history of PMD Review of PMD natural history studies Summary of PMD natural history studies highlighting trends in phenotype, biochemical markers, genotype-phenotype correlation, and prognosis [3] Genomic diagnosis
Genomic diagnosis of PMD Summarizes state of PMD diagnosis, proposes genomic sequencing as the first step [87] Approaches to diagnosis of PMD Summary of different approaches to genomic sequencing for diagnosis of PMD and utility of databases and '-omics' to aid in variant interpretation [7] Treatment PMD treatment Summary of existing therapies (mitochondrial supplemental medicines, exercise) and emerging therapies (both specific to the gene defect and universal) [88] Recent advances in understanding of mitochondrial pathophysiology and therapies
Overview of mitochondrial function, genomics, transcriptomics, proteomics, metabolomics, mitochondrial disease pathogenesis, and therapies
Genomic-based therapies for mtDNArelated PMD Summary of technology for prevention of mtDNA transmission, mtDNA heteroplasmy shifting, and CRISPR [89] mitochondrial disease may remain complex and burdensome. Grier et al. recently described the diagnostic odyssey in patients with self-reported mitochondrial disease and found that, on average, individuals saw eight different physicians and underwent many tests before receiving a diagnosis of PMD [93] . More than half of the individuals surveyed reported receiving an incorrect clinical diagnosis prior to receiving their PMD diagnosis.
TOOLS AND RESOURCES FOR ASSESSING GENOMIC VARIANTS RELATED TO PRIMARY MITOCHONDRIAL DISEASE
With improving genomic sequencing technologies and increased global utilization of massively parallel diagnostic tests, the need for robust bioinformatics tools and data resources to accurately curate novel disease genes and variants for PMD has been well recognized.
The Mitochondrial Disease Sequence Data Resource (MSeqDR) is an online, centralized Web portal that organizes both nuclear and mtDNA variants in all known and candidate genes for PMD [35, 94, 95] . Available through this resource are tools both to provide comprehensive information on variants and genes, and to assist clinicians and researchers in efficiently mining genomic data. MSeqDR has partnered with the Clinical Genome Resource, ClinGen, to form a mitochondrial disease expert panel to enable expert curation of variants and novel disease genes associated with PMD [96] . MSeqDR also now provides mtDNA variant manually-curated assertions from MITOMAP, the gold-standard resource for mtDNA variant curation [97] . In addition, MSeqDR and MITOMAP incorporate data from an informatics tool recently developed to predict effects of novel mitochondrial tRNA variants (mito-TIP) [98] , and also HmtDB and HmtVAR -databases of mtDNA sequences, variants, and their predicted effects [99] . MSeqDR custom tools are available to support PMD gene and variant submission by users or expert panels that are linked to ClinVar. Further, MSeqDR mvTool [94] is a recently launched Web and API resource for comprehensive variant annotation, universal nomenclature collation, and reference genome conversion for mtDNA.
Lastly, there exist two tools that are regularly updated for variants in POLG -a relatively common nuclear gene cause of PMD that may manifest with a wide variety of phenotypes [100] . Before their common underlying genetic cause was understood, the broad phenotypic spectrum of POLG-related diseases was organized into at least eight discrete clinical syndromes ranging from Alpers-Huttenlocher syndrome that involves childhood-onset severe epilepsy and hepatic failure, to adult-onset isolated progressive external ophthalmoplegia (PEO), to ataxia neuropathy spectrum disorder or Parkinsonism [101] . Pathogenic variants in POLG are now recognized to cause a spectrum of medical concerns that may be inherited in either an autosomal dominant or autosomal recessive pattern, with varying and progressive clinical features such as intractable epilepsy, Leigh syndrome, neuropathy, ataxia, hearing loss, ophthalmoplegia, and hepatic failure. More recent phenotype descriptions include hypogonadism, ovarian dysfunction [77] , fetal cerebellar growth arrest [78] , early-onset cataracts [79] , and elevated CSF protein [80] . As strong genotype-phenotype correlations are recognized to occur in POLG-related disorders, POLG variants have been expertly curated and catalogued in the Human DNA Polymerase Gamma Mutation Database (https://tools.niehs.nih.gov/polg/). In addition, with recent recognition that there are distinct biochemical domains within the POLG protein, known or novel variants falling within specific predesignated clusters often have characteristic phenotypic effects that can be evaluated in an easily accessible online tool -the POLG variant server [102] .
CLINICAL TRIALS FOR PRIMARY MITOCHONDRIAL DISEASES
Whereas there are no cures or US Food and Drug Administration-approved drugs for PMD, several therapeutic PMD strategies are now being evaluated in clinical trials. The lack of validated biomarkers and outcome measures of PMD disease progression, limited natural history data, and inherent variability and fluctuations in PMD course impose intrinsic challenges to conducting PMD clinical trials. Several clinical trials are underway for treating PMD [90] . In effort to improve trial enrollment in the mitochondrial disease patient community, a recent publication reported survey results of affected individuals and their family members performed to ascertain PMD patient motivations and barriers to clinical trial participation [4 & ]. Both adults and children with PMD prioritized weakness, exercise intolerance, fatigue, imbalance, and gastrointestinal involvement, along with developmental delay in children, as their predominant concerns they would most like to be evaluated in clinical trials.
CONCLUSION
Since the first discovery of a molecular etiology for primary mitochondrial disease 30 years ago [103] , the field of mitochondrial genetics has advanced rapidly in the molecular era with at least 15-20 PMD genes discovered each year for the past decade [104] . Genomic diagnosis has become the frontline testing modality, enabling an increasingly broader spectrum of clinical phenotypes to be identified including atypical and less severe presentations. Nevertheless, many individuals with features highly concerning for PMD remain undiagnosed, highlighting that gaps still remain in our knowledge of the genetic basis of mitochondrial disease. Identifying the genetic basis of disease in each patient is particularly important, as the development of effective, precision therapies requires improved understanding of underlying PMD cause and mitochondrial pathophysiology.
